TeGenero
TeGenero was a biotechnology company in Würzburg . It had 15 employees and had been a public company since April 2002 . TeGenero GmbH was founded in 2000 as a spin-off from the medical faculty of the Würzburg University around the immunologist Thomas Hünig , and received 14 million euros in venture capital .
The first product from TeGenero was the antibody TGN1412 , which caused life-threatening side effects in the six test subjects in the first clinical test on humans in March 2006 .
In July 2006, TeGenero filed for bankruptcy , as no further financial resources could be raised since the incident that would be necessary for the continuation of the company. The remains were bought by a Russian investor who continues the company as Theramab GmbH . The managing director is Sergej Chuvpilo.
Individual evidence
- ↑ Würzburg company TeGenero insolvent (tagesschau.de archive)
- ↑ biotechnologie.de: Tegenero case rolled up: Researchers clarify the mechanism of action of the antibody ( memento of the original from July 17, 2010 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , April 4, 2008
